Valeant just had to tell Wall Street about its new cataclysmic problem

Valeant Pharmaceuticals on Tuesday morning reported a Q1 earnings loss of $373.7 million, or $1.08 a share.It also cut guidance for the rest of the year. The stock has fallen 16% in Tuesday's trading day.
There was one piece of information that really upset Wall Street.You could tell because analysts kept asking about it over and over again on the earnings call. It had to do with Valeant's new agreement to sell drugs primarily through Walgreen's.
The problem is simple to exp